Ongoing Assessments & Recent Research.
Easy access to our work
Alzheimer’s Disease
May 2021Anemia in Chronic Kidney Disease
Feb 2021Atopic Dermatitis
Jul 2021COVID-19
Jul 2020High Cholesterol
Feb 2021Lupus Nephritis
Mar 2021Multiple Myeloma
Apr 2021PTSD: Service Dogs
Nov 2021Unsupported Price Increases
Jan 2021Featured News & Insights.
Learn about our latest work.
ICER Publishes Evidence Report on Therapies for High Cholesterol
The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000. Bempedoic acid provides a new oral treatment option that may be helpful particularly for patients who are not able to take […]
01/22/2021ICER Releases Draft Evidence Report on Therapies for Lupus Nephritis
Public comment period now open until February 18, 2021; Requests to make oral comment during public meeting also being accepted.
01/22/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19
This white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies.
Cornerstones of ‘Fair’ Drug Coverage
Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
Learn more about ICER’s Health Technology Assessment Fellowship! And click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.